These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36289788)

  • 1. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.
    Haga K; Shibuya T; Osada T; Sato S; Fukuo Y; Kobayashi O; Yamada T; Asaoka D; Ito K; Nomura K; Haraikawa M; Nomura O; Fukushima H; Murakami T; Ishikawa D; Hojo M; Nagahara A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China.
    Yan J; Ding X; Wu J; Liu A; Fang L; Xu Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38759. PubMed ID: 38968537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis.
    Kakiuchi T; Yoshiura M
    Clin Ther; 2022 Jul; 44(7):1028-1032. PubMed ID: 35779956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan.
    Yokoyama K; Yamamoto Y; Nambu R; Hagiwara SI; Abukawa D; Mizuochi T; Kudo T; Sado T; Iwata N; Ishige T; Iwama I; Kumagai H; Arai K; Shimizu T
    J Gastroenterol Hepatol; 2023 Jul; 38(7):1107-1115. PubMed ID: 37278369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.
    Huang K; Liu J; Xia W; Tian C; Yao L; Cao Q; Chen H
    Front Pharmacol; 2023; 14():1188751. PubMed ID: 37214457
    [No Abstract]   [Full Text] [Related]  

  • 7. [Explore the influence of vitamin D supplementation on clinical efficacy and drug retention rate of vedolizumab in patients with ulcerative colitis].
    Xiao HY; Rao SY; Zhang DL; Ma GL; Xu Y; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(23):1759-1766. PubMed ID: 37305935
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
    Sablich R; Urbano MT; Scarpa M; Scognamiglio F; Paviotti A; Savarino E
    Sci Rep; 2023 Feb; 13(1):1816. PubMed ID: 36725872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness.
    Zezos P; Kabakchiev B; Weizman AV; Nguyen GC; Narula N; Croitoru K; Steinhart AH; Silverberg MS
    J Can Assoc Gastroenterol; 2020 Apr; 3(2):74-82. PubMed ID: 32328546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
    Takatsu N; Hisabe T; Higashi D; Ueki T; Matsui T
    Core Evid; 2020; 15():7-20. PubMed ID: 32280316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
    Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
    Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).
    Reenaers C; Cremer A; Dewit O; De Vroey B; Van Moerkercke W; Bossuyt P; Muls V; Imschoot J; Block S; Hantson A; Van Hootegem P
    Acta Gastroenterol Belg; 2020; 83(1):15-23. PubMed ID: 32233267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.